{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:26:11Z","timestamp":1773692771736,"version":"3.50.1"},"reference-count":151,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.autrev.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:20:32Z","timestamp":1467796832000},"page":"870-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach"],"prefix":"10.1016","volume":"15","author":[{"given":"Hani S.","family":"Mousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Malinverno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10003","key":"10.1016\/j.autrev.2016.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"issue":"8537","key":"10.1016\/j.autrev.2016.07.003_bb0010","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"329","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2016.07.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2015-310593","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","author":"Beuers","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2016.07.003_bb0025","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/ajg.2015.312","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"110","author":"Beuers","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jhep.2015.06.031","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"63","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0035","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.28140","article-title":"Changing nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019","volume":"62","author":"Beuers","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0040","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.clinre.2015.08.001","article-title":"Changing nomenclature for PBC","volume":"39","author":"Beuers","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0045","doi-asserted-by":"crossref","first-page":"G161","DOI":"10.1152\/ajpgi.1980.239.3.G161","article-title":"Metabolism in man of 7-ketolithocholic acid: precursor of cheno-and ursodeoxycholic acids","volume":"239","author":"Fromm","year":"1980","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/hep.510290220","article-title":"Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis","volume":"29","author":"Invernizzi","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1517\/14728214.2016.1150999","article-title":"Emerging drugs for the treatment of primary biliary cholangitis","volume":"21","author":"Ali","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"issue":"12","key":"10.1016\/j.autrev.2016.07.003_bb0065","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2009.08.008","article-title":"Immune tolerance: what is unique about the liver","volume":"34","author":"Tiegs","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2016.07.003_bb0090","series-title":"Breach of tolerance: primary biliary cirrhosis","author":"Wang","year":"2014"},{"issue":"7","key":"10.1016\/j.autrev.2016.07.003_bb0095","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.4049\/jimmunol.141.7.2321","article-title":"Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function","volume":"141","author":"Van de Water","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2016.07.003_bb0100","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0105","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0110","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.1840110504","article-title":"Sj\u00f6gren's syndrome in patients with primary biliary cirrhosis","volume":"11","author":"Tsianos","year":"1990","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0115","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/hep.24414","article-title":"Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving","volume":"54","author":"Invernizzi","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.1840100405","article-title":"A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss","volume":"10","author":"Mitchison","year":"1989","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2016.07.003_bb0125","first-page":"A118","article-title":"PMO-112 Is primary biliary cirrhosis a steroid sensitive autoimmune disease?","volume":"61","author":"Dhanda","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8278(96)80327-8","article-title":"Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis","volume":"25","author":"Leuschner","year":"1996","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0135","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0145","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0150","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1568-9972(02)00122-2","article-title":"T cell immunity and primary biliary cirrhosis","volume":"2","author":"Ishibashi","year":"2003","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF00915293","article-title":"T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls","volume":"4","author":"Si","year":"1984","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/gene.2013.1","article-title":"Pathway-based analysis of primary biliary cirrhosis genome-wide association studies","volume":"14","author":"Kar","year":"2013","journal-title":"Genes Immun"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0175","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1023\/A:1020511002025","article-title":"Cytokine profile in the liver of primary biliary cirrhosis","volume":"19","author":"Nagano","year":"1999","journal-title":"J Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0180","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/eji.201344270","article-title":"Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis","volume":"44","author":"Carbone","year":"2014","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0185","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2016.07.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"issue":"6939","key":"10.1016\/j.autrev.2016.07.003_bb0195","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0205","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0168-8278(00)80213-5","article-title":"CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis","volume":"32","author":"Agarwal","year":"2000","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.arcmed.2011.04.004","article-title":"Association between CTLA-4 exon-1+ 49A>G polymorphism and primary biliary cirrhosis risk: a meta-analysis","volume":"42","author":"Huang","year":"2011","journal-title":"Arch Med Res"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/hep.22048","article-title":"Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis","volume":"47","author":"Juran","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0225","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.182.3.1325","article-title":"MicroRNA-513 regulates B7-H1 translation and is involved in IFN-\u03b3-induced B7-H1 expression in cholangiocytes","volume":"182","author":"Gong","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2016.07.003_bb0230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1440-1827.2007.02129.x","article-title":"Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease","volume":"57","author":"Oikawa","year":"2007","journal-title":"Pathol Int"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0235","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","article-title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases","volume":"102","author":"Mataki","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0240","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.24630","article-title":"Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis","volume":"55","author":"Lleo","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0250","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/eji.1830260216","article-title":"CD40\/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages","volume":"26","author":"Kennedy","year":"1996","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2016.07.003_bb0255","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.4049\/jimmunol.1500922","article-title":"Interaction of macrophage antigen 1 and CD40 ligand leads to IL-12 production and resistance in CD40-deficient mice infected with Leishmania major","volume":"195","author":"Okwor","year":"2015","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2016.07.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014037","article-title":"Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand","volume":"5","author":"Humphreys","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0265","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/cmi.2010.40","article-title":"CD4+CD25+ but not CD4+Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis","volume":"7","author":"Wang","year":"2010","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0275","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaut.2010.06.004","article-title":"Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis","volume":"35","author":"Bernuzzi","year":"2010","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaut.2011.01.001","article-title":"IL-2: a two-faced master regulator of autoimmunity","volume":"36","author":"Sharma","year":"2011","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0285","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2006.10.007","article-title":"CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked\u2013like syndrome, and defective IL-10 expression from CD4 lymphocytes","volume":"119","author":"Caudy","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0290","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/hep.21385","article-title":"IL-2 receptor \u03b1\u2212\/\u2212 mice and the development of primary biliary cirrhosis","volume":"44","author":"Wakabayashi","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2006.04.005","article-title":"IL-2 receptor alpha deficiency and features of primary biliary cirrhosis","volume":"27","author":"Aoki","year":"2006","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0300","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12415","article-title":"Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3+ regulatory T cells","volume":"178","author":"Tanaka","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"46.10","key":"10.1016\/j.autrev.2016.07.003_bb0305","first-page":"3389","article-title":"Regulatory T cells as immunotherapy","volume":"5","author":"Singer","year":"2014","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2016.07.003_bb0310","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.4049\/jimmunol.161.8.3912","article-title":"B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice","volume":"161","author":"Serreze","year":"1998","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0315","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.174.6.3781","article-title":"Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis","volume":"174","author":"O'Neill","year":"2005","journal-title":"J Immunol"},{"issue":"52","key":"10.1016\/j.autrev.2016.07.003_bb0320","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.20051438","article-title":"B cell\u2013deficient NOD. H-2h4 mice have CD4+ CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis","volume":"203","author":"Yu","year":"2006","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.autrev.2016.07.003_bb0330","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1172\/JCI32405","article-title":"Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice","volume":"117","author":"Hu","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0340","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0345","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.510250103","article-title":"Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression","volume":"25","author":"Van Norstrand","year":"1997","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.autrev.2016.07.003_bb0350","article-title":"Paradox of B cell\u2013targeted therapies","volume":"118","author":"Kurosaki","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0355","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI104909","article-title":"The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption","volume":"43","author":"Hofmann","year":"1964","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.autrev.2016.07.003_bb0360","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0365","first-page":"305","article-title":"Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat","volume":"65","author":"Kountouras","year":"1984","journal-title":"Br J Exp Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0370","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.toxlet.2014.04.001","article-title":"Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice","volume":"228","author":"Woolbright","year":"2014","journal-title":"Toxicol Lett"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0375","first-page":"471","article-title":"Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria","volume":"19","author":"Kr\u00e4henb\u00fchl","year":"1994","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-8278(98)80208-0","article-title":"Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes","volume":"28","author":"Benz","year":"1998","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0385","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.47.5.710","article-title":"Evidence of a systemic phenomenon for oxidative stress in cholestatic liver disease","volume":"47","author":"Ljubuncic","year":"2000","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0390","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-2275(20)43025-1","article-title":"Feedback regulation of bile acid biosynthesis in the rat","volume":"10","author":"Sarah","year":"1969","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0400","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0405","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0410","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"51","key":"10.1016\/j.autrev.2016.07.003_bb0415","doi-asserted-by":"crossref","first-page":"51085","DOI":"10.1074\/jbc.M308321200","article-title":"Farnesoid X receptor activates transcription of the phospholipid pump MDR3","volume":"278","author":"Huang","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0420","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1053\/gast.2001.23984","article-title":"The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood","volume":"120","author":"Jacquemin","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2016.07.003_bb0425","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1172\/JCI0215968","article-title":"The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II","volume":"110","author":"Wang","year":"2002","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.autrev.2016.07.003_bb0430","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.bbalip.2012.07.004","article-title":"Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms","volume":"1821","author":"Hollman","year":"2012","journal-title":"Biochim Biophys Acta, Mol Cell Biol Lipids"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0435","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0440","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","article-title":"Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.autrev.2016.07.003_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043044","article-title":"FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model","volume":"7","author":"Deuschle","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0450","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep.23390","article-title":"Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"issue":"5418","key":"10.1016\/j.autrev.2016.07.003_bb0455","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.autrev.2016.07.003_bb0460","series-title":"Hepatology","article-title":"The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC","author":"Kowdley","year":"2011"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0465","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.autrev.2016.07.003_bb0470","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2016.07.003_bb0475","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbalip.2006.09.018","article-title":"Effects of FXR in foam-cell formation and atherosclerosis development","volume":"1761","author":"Guo","year":"2006","journal-title":"Biochim Biophys Acta, Mol Cell Biol Lipids"},{"issue":"10","key":"10.1016\/j.autrev.2016.07.003_bb0480","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1161\/01.ATV.0000235697.35431.05","article-title":"FXR deficiency causes reduced atherosclerosis in Ldlr\u2212\/\u2212 mice","volume":"26","author":"Zhang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.autrev.2016.07.003_bb0485","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1194\/jlr.M038141","article-title":"Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice","volume":"54","author":"Gautier","year":"2013","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0490","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (\u2212\/\u2212) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0495","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/MCB.14.3.1544","article-title":"A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements","volume":"14","author":"Baes","year":"1994","journal-title":"Mol Cell Biol"},{"issue":"38","key":"10.1016\/j.autrev.2016.07.003_bb0500","doi-asserted-by":"crossref","first-page":"23565","DOI":"10.1074\/jbc.272.38.23565","article-title":"Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR","volume":"272","author":"Choi","year":"1997","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0505","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","article-title":"CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice","volume":"42","author":"Wagner","year":"2005","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.autrev.2016.07.003_bb0510","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1074\/jbc.M310258200","article-title":"Feed-forward regulation of bile acid detoxification by CYP3A4 STUDIES IN HUMANIZED TRANSGENIC MICE","volume":"279","author":"Stedman","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0515","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/dmd.32.1.35","article-title":"The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes","volume":"32","author":"Song","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0520","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0016-5085(90)90027-X","article-title":"Rifampin relieves pruritus in children with cholestatic liver disease","volume":"98","author":"Cynamon","year":"1990","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0525","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.autrev.2016.07.003_bb0530","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1073\/pnas.130155097","article-title":"St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor","volume":"97","author":"Moore","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2016.07.003_bb0535","first-page":"238","article-title":"A pharmacodynamic study of compound Hypericum perforatum granule","volume":"15","author":"Yuhua","year":"2004","journal-title":"Tradis Chin Drug Res Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2007.08.031","article-title":"Hepatoprotective effect of Hypericum japonicum extract and its fractions","volume":"116","author":"Wang","year":"2008","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0545","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jhep.2002.30084","article-title":"Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis","volume":"35","author":"Vogel","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0550","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jhep.2009.01.015","article-title":"Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations","volume":"50","author":"Tanaka","year":"2009","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.autrev.2016.07.003_bb0555","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00042737-200207000-00004","article-title":"Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis","volume":"14","author":"Lakatos","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2016.07.003_bb0560","series-title":"Hepatology","article-title":"High dose vitamin D3 treatment enhances macrophage phagocytosis of apoptotic cells and lowers bilirubin levels in PBC","author":"Allina","year":"2008"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0565","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaut.2006.11.004","article-title":"T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis","volume":"27","author":"Allina","year":"2006","journal-title":"J Autoimmun"},{"issue":"11","key":"10.1016\/j.autrev.2016.07.003_bb0570","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"AG protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2016.07.003_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00287","article-title":"The G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits gastric inflammation through antagonizing NF-kB signaling pathway","volume":"6","author":"Guo","year":"2015","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0580","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2212\/\u2212(Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO 3\u2212 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0585","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.26463","article-title":"The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice","volume":"58","author":"P\u00e9an","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.autrev.2016.07.003_bb0590","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2016.07.003_bb0595","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00398.2012","article-title":"Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids","author":"Zhang","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2016.07.003_bb0600","unstructured":"!!! INVALID CITATION !!! {}."},{"key":"10.1016\/j.autrev.2016.07.003_bb0605","article-title":"ASBT inhibitors in cholangiopathies\u2014good for mice, good for men?","author":"Poupon","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0610","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO3\u2212 umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0615","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A biliary HCO3\u2212 umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2016.07.003_bb0620","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0016-5085(93)90735-U","article-title":"Abnormal expression of anion exchanger biliary cirrhosis","volume":"105","author":"PRIETO","year":"1993","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.autrev.2016.07.003_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012403","article-title":"Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis","volume":"5","author":"Hov","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.autrev.2016.07.003_bb0630","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20943","article-title":"Novel biotransformation and physiological properties of norursodeoxycholic acid in humans","volume":"42","author":"Hofmann","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.autrev.2016.07.003_bb0635","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport atid effect tin biliary secretion of 23=Nor-ursodeoxycholate in rodents","volume":"90","author":"Yoon","year":"1986","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0640","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0645","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000371904","article-title":"Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders","volume":"33","author":"Trauner","year":"2015","journal-title":"Dig Dis"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0650","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00535-013-0795-0","article-title":"Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients","volume":"49","author":"Ohishi","year":"2014","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0655","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/liv.12526","article-title":"Pathophysiological analysis of primary biliary cirrhosis focusing on choline\/phospholipid metabolism","volume":"35","author":"Kohjima","year":"2015","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0660","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.105.093765","article-title":"Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor \u03b1","volume":"317","author":"Moffit","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0665","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/gast.1996.v111.pm8698195","article-title":"Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene","volume":"111","author":"Van Nieuwkerk","year":"1996","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.autrev.2016.07.003_bb0670","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00535-003-1432-0","article-title":"Partial characterization of cytoprotective mechanisms of lecithin against bile salt-induced bile duct damage","volume":"39","author":"Tsuboi","year":"2004","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0675","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","article-title":"Fibrates down-regulate IL-1\u2013stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkB\u2013C\/EBP-\u03b2 complex formation","volume":"101","author":"Kleemann","year":"2003","journal-title":"Blood"},{"issue":"47","key":"10.1016\/j.autrev.2016.07.003_bb0680","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkB\u03b1 expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-\u03b1 activators","volume":"275","author":"Delerive","year":"2000","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0685","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"s3","key":"10.1016\/j.autrev.2016.07.003_bb0690","doi-asserted-by":"crossref","DOI":"10.1111\/j.1872-034X.2007.00232.x","article-title":"Fibrate for treatment of primary biliary cirrhosis","volume":"37","author":"Iwasaki","year":"2007","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0695","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2016.07.003_bb0700","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0705","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0710","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0715","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.autrev.2016.07.003_bb0720","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/ajg.2015.163","article-title":"Combination therapy of ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis: the end of the steroid era in autoimmune liver diseases?","volume":"110","author":"Licinio","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0725","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0730","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2005.02.052","article-title":"Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2","volume":"43","author":"Vadasz","year":"2005","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2016.07.003_bb0735","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin \u03b1v\u03b26 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2016.07.003_bb0740","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00535-010-0351-0","article-title":"A polymorphism in the integrin \u03b1V subunit gene affects the progression of primary biliary cirrhosis in Japanese patients","volume":"46","author":"Inamine","year":"2011","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0745","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin \u03b1v\u03b26 on cholangiocytes blocks transforming growth factor-\u03b2 activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2016.07.003_bb0750","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2015.05.001","article-title":"Hepatic regenerative medicine","volume":"63","author":"Mazza","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2016.07.003_bb0755","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.onc.1210623","article-title":"Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models","volume":"27","author":"Desnoyers","year":"2008","journal-title":"Oncogene"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216301380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:03:37Z","timestamp":1748995417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216301380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":151,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1568997216301380"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}